Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.85    0.10 (3.64%)
Bid:
2.75
Ask:
2.85
Spread: 0.10 (3.636%)
Market Cap: £5.20m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

PrimaryBid.com Offer

15 Jul 2020 17:20

RNS Number : 1337T
Nanoco Group PLC
15 July 2020
Β 

Β 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 ("FSMA") AND HAS BEEN APPROVED BY PRIMARYBID LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRNΒ 779021)

Β 

15 July 2020

Β 

Nanoco Group plc

("Nanoco" or the "Company") (LON:NANO)

PrimaryBid.com Offer

Β 

Nanoco Group plc (LON:NANO),Β a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from its technology platform, is pleased to announceΒ an offer for subscription via PrimaryBid (the "PrimaryBid Offer") of new ordinary shares of 10p each in the Company ("New Ordinary Shares")Β at an issue price of 17.5 pence per New Ordinary Share (the "Issue Price"), being a discount of 2.8% per cent to the closing mid-price on 15 July 2020 as announced earlier on 15 July 2020 .

The PrimaryBid Offer is conditional on the new Ordinary Shares to be issued pursuant to the PrimaryBid Offer being admitted to listing on the Official List by the Financial Conduct Authority and to trading by the London Stock Exchange on its main market for listed securities ("Admission").Β Admission is expected to be take place at 8.00 a.m. on 20 July 2020.

The net proceeds of the Fundraising will be used to extend the Company's cash runway at least to the end of calendar year 2021 while supporting its core IP assets and its business operations during the ongoing lawsuit against Samsung.

The Company's largest shareholder, Lombard Odier, has undertaken to subscribe for Β£2.14m of New Ordinary Shares on the same terms as those set out above, which subscription shall be subject to claw back depending on the amount of the other aggregate applications received from other investors under the PrimaryBid Offer. Lombard Odier will receive, conditional upon Admission (as defined below), a subscription commission equal to 3.0 per cent of the amount it subscribes . In the event that Admission does not occur, Lombard Odier will not receive any commission payment. .

Certain directors of the Company and/or persons closely associated with them have given written undertakings to the Company to subscribe for PrimaryBid Shares at the Issue Price with a total value of Β£61,000.

PrimaryBid Offer

The Company values its retail investor base and is therefore pleased to provide private and other investors the opportunity to participate in the PrimaryBid Offer by applying exclusively through the www.PrimaryBid.com platform and the PrimaryBid mobile app available on the Apple App Store and Google Play. PrimaryBid does not charge investors any commission for this service.

The PrimaryBid Offer, via the PrimaryBid.com platform, will be open to individual and institutional investors immediately following this announcement and will close at 9:00 p.m. on 15Β July 2020. The PrimaryBid Offer may close early if it is oversubscribed.

Subscriptions under the PrimaryBid Offer will be considered by the Company on a "first come, first served" basis, subject to conditions (which are available to view on PrimaryBid.com).

The Company in consultation with PrimaryBid reserves the right to scale back any order at its discretion. The Company and PrimaryBid reserve the right to reject any application for subscription under the Offer without giving any reason for such rejection. It is not intended that the Director orders be subject to scale back.

No commission is charged to investors on applications to participate in the PrimaryBid Offer made through PrimaryBid. It is vital to note that once an application for New Ordinary Shares has been made and accepted via PrimaryBid, an application cannot be withdrawn.

For further information on PrimaryBid.com or the procedure for applications under the PrimaryBid Offer, visitΒ www.PrimaryBid.comΒ or call PrimaryBid.com on +44 20 3026 4750.Β 

The New Ordinary Shares will be issued free of all liens, charges and encumbrances and will, when issued and fully paid, rankΒ pari passuΒ in all respects with the Company's existing Ordinary Shares.

Nanoco Group PLC

Michael Edelman, CEO

Brian Tenner, COO & CFO

Caroline Watson, Investor Relations Manager

Β 

+44 (0) 161 603 7900

PrimaryBid Limited

James Deal / Kieran D'Silva

Β 

+ 44 (0) 203 026 4750

Further Details of the Offer

The Company highly values its retail investor base which has supported the Company alongside institutional investors over several years. Given the longstanding support of retail shareholders, the Company believes that it is appropriate to provide retail and other interested investors the opportunity to participate in the Offer. The Company is therefore making the Offer available exclusively through PrimaryBid.com.

The Offer is offered under the exemptions against the need for a prospectus allowed under the Prospectus Rules. As such, there is no need for publication of aΒ prospectus pursuant to the Prospectus Rules, or for approval of the same by the Financial Conduct Authority in its capacity as the UK Listing Authority. The Offer is not being made into any Restricted Jurisdiction or any other jurisdiction where it would be unlawful to do so.

There is a minimum subscription of Β£100 per investor under the terms of the Offer which is open to existing shareholders and other investors subscribing via PrimaryBid.com. This allocation will be filled on a "first come first served" basis.

For further details please refer to the PrimaryBid.com website atΒ www.PrimaryBid.com. The terms and conditions on which the Offer is made, including the procedure for application and payment for New Ordinary Shares, is available to all persons who register with PrimaryBid.com.

Investors should make their own investigations into the merits of an investment in the Company. Nothing in this announcement amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice.

It should be noted that a subscription for New Ordinary Shares and investment in the Company carries a number of risks. Investors should consider the risk factors set out on PrimaryBid.com before making a decision to subscribe for New Ordinary Shares. Investors should take independent advice from a person experienced in advising on investment in securities such as the New Ordinary Shares if they are in any doubt.Β 

Β 

Β 

END

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
OFFBLGDRXBBDGGU
Date   Source Headline
15th Oct 201310:53 amRNSPlacing to raise £10m
14th Oct 20137:00 amRNSPreliminary Results
27th Sep 20137:00 amRNSCorporate Update
27th Aug 20137:00 amRNSNotification of Preliminary Results
13th Aug 20131:22 pmRNSHolding(s) in Company
13th Aug 201311:45 amRNSHolding(s) in Company
5th Aug 20136:09 pmRNSTotal Voting Rights
5th Aug 20131:19 pmRNSHolding(s) in Company
26th Jul 20135:14 pmRNSDirector's Dealings
9th Jul 20131:58 pmRNSHolding(s) in Company
25th Jun 20133:30 pmRNSHolding(s) in Company
17th Jun 20137:00 amRNSHolding(s) in Company
12th Jun 20137:00 amRNSBlocklisting Interim Review
31st May 20132:43 pmRNSHolding(s) in Company
31st May 20139:22 amRNSHolding(s) in Company
15th May 20134:45 pmRNSHolding(s) in Company
14th May 20135:52 pmRNSHolding(s) in Company
9th May 201312:30 pmRNSRelocation of CEO to the US and Director Dealings
2nd May 20137:00 amRNSSigns Follow-on Agreement
29th Apr 20137:00 amRNSBoard Changes
24th Apr 20137:00 amRNSHolding(s) in Company
11th Apr 20134:46 pmRNSHolding(s) in Company
11th Apr 20137:00 amRNSHolding(s) in Company
28th Mar 20132:00 pmRNSAppointment of Joint Broker
27th Mar 20132:20 pmRNSHolding (s) in Company
18th Mar 20137:00 amRNSInterim Results
15th Feb 20132:08 pmRNSHolding(s) in Company
14th Feb 20131:00 pmRNSHolding(s) in Company
12th Feb 20139:49 amRNSHolding(s) in Company
6th Feb 20137:00 amRNSAppointment of Key Business Development Executives
29th Jan 20134:18 pmRNSHolding(s) in Company
28th Jan 20136:06 pmRNSHolding(s) in Company
24th Jan 20135:51 pmRNSHolding(s) in Company
23rd Jan 20137:00 amRNSLicensing Agreement with Dow Chemical
21st Jan 20137:00 amRNSNotification of Interim Results
11th Jan 20138:59 amRNSHolding(s) in Company
10th Jan 20131:19 pmRNSHolding(s) in Company
20th Dec 20127:00 amRNSSigns further agreement with Tokyo Electron
14th Dec 201210:25 amRNSResult of AGM
14th Dec 20127:00 amRNSAGM Statement
12th Dec 20123:37 pmRNSBlock Listing Application
4th Dec 20127:00 amRNSExercise of Options
12th Nov 20127:00 amRNSPosting of Annual Report & Accounts
23rd Oct 20127:00 amRNSGrant of Options
19th Oct 201212:43 pmRNSDirectors' Dealings and Exercise of Options
15th Oct 20127:00 amRNSPreliminary Results
5th Oct 20127:00 amRNSFollow-on Lighting Agreement
5th Sep 20127:00 amRNSNotification of Preliminary Results
20th Aug 20127:00 amRNSWins Government Grants
1st Aug 20127:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.